Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An expanded access study of SLS-005 (Trehalose) for Sanfilippo Syndrome

Next Previous
Trial Profile

An expanded access study of SLS-005 (Trehalose) for Sanfilippo Syndrome

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trehalose (Primary)
  • Indications Mucopolysaccharidosis III
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 15 Jul 2019 According to a Seelos Therapeutics media release, Team Sanfilippo Foundation (TSF) and Seelos Therapeutics will continue to work aggressively to raise additional funds to accommodate as many children as possible into this expanded access program.
  • 15 Jul 2019 According to a Seelos Therapeutics media release, Seelos announced today the receipt of a grant from Team Sanfilippo Foundation.The grant will be used towards the funding of the FDA/EMA Open-Label Phase IIb/III Study in Sanfilippo Syndrome type A and B (CT Profile: 304671) and this separate expanded access study for Sanfilippo type C and D as well as type A and B patients who do not meet the trial entry criteria (CT profile 307744).
  • 06 Jun 2019 According to a Seelos Therapeutics media release, Dr. Wasiewski will lead the collaboration with Team Sanfilippo Foundation (TSF) to spearhead this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top